ClinicalTrials.gg
CompletedNCT02091141Updated Jul 23, 2024Results posted

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

A Phase 2 interventional study of Trastuzumab and Pertuzumab in Neoplasms, Solid Tumors and Biliary Cancer, sponsored by Genentech, Inc.. Completed at 60 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-23.

Primary conditionUrinary Bladder NeoplasmsRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Urinary Bladder Neoplasms
Why
  1. The study's listed conditions name Urinary Bladder Neoplasms, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
673
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Urinary Bladder Neoplasms by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Urinary Bladder Neoplasms · Hoffmann-La Roche.

Enrollment
4th of 10
673 · median 292
Started
2014
with 2 others
Phase 2
4 of 10
none open now
Registered
1st of 10
by date

Among the 10 studies in Urinary Bladder Neoplasms by Hoffmann-La Roche, this one is the 4th largest by enrollment, is one of 3 that started in 2014, is one of 4 in phase 2, and was the 1st registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

None of the 10 studies in Urinary Bladder Neoplasms by Hoffmann-La Roche is open now. The open studies under Urinary Bladder Neoplasms, anywhere →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Urinary Bladder Neoplasms by Hoffmann-La Roche as a file.
02

Study summary

This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.

03

Conditions studied

  • Neoplasms
  • Solid Tumors
  • Biliary Cancer
  • Salivary Cancer
  • Bladder Cancer

Browse trials for

04

In context

Urinary Bladder Neoplasms Reclassified

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

This study's enrollment of 673 is above the median of 60 across 1,296 interventional studies indexed under Urinary Bladder Neoplasms.

Browse Urinary Bladder Neoplasms studies →

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Compared within Urinary Bladder Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

General Inclusion Criteria:

  • greater than or equal to (≥) 12 weeks
  • documented cancer (solid tumors, not including hematologic )
  • Participants who have received standard therapy for metastatic cancer (except for the tumors for which no first-line therapy exists) and in whom a trial of targeted therapy is considered the best available treatment option. Eligible participants should not have available therapies that will convey clinical benefit and/or are not suitable options per the treating physician's judgment
  • No previous treatment with the specific assigned study drug or any other drug sharing the same target
  • by v1.1
  • Performance Status (ECOG PS) score of 0 or 1 (For patients enrolling in the atezolizumab arm, ECOG score must be documented within 7 days prior to first treatment and confirmation of ECOG PS must be entered into the interactive web response system [IWRS] prior to initiation of treatment)
  • Adequate hematologic, renal, and liver function as defined by the protocol
  • If applicable, use of methods or abstinence as defined by the protocol

Study-Drug Specific Inclusion Criteria:

Trastuzumab plus Pertuzumab

  • Molecular testing results from clinical laboratory improvement amendments (CLIA)-certified laboratories (using tissue and/or blood) demonstrating overexpression or amplification. Participants must have one of the following tumor types: biliary cancer, salivary cancer, or bladder cancer

    a) For participants screened using a blood assay: obtain tissue-based testing result confirming study eligibility (within first 4 weeks after enrollment)

  • (LVEF) greater than (>) 50 percent (%) or above the lower limit of the institutional normal range, whichever is lower
  • Availability of an archival or new pre-treatment tissue sample is required if molecular testing was not performed by Foundation Medicine. Any available tumor tissue sample can be submitted. The tissue sample must be submitted within 4 weeks after enrollment

Erlotinib

  • Molecular testing results from CLIA-certified laboratories (using tissue and/or blood) demonstrating epidermal growth factor receptor (EGFR)-activating mutations

Vemurafenib plus Cobimetinib

  • Molecular testing results from CLIA-certified laboratories (using tissue and/or blood) demonstrating BRAF V600 mutations a) For participants screened using a blood assay: obtain tissue-based testing result confirming study eligibility (within first 4 weeks after enrollment)

Vismodegib

  • Molecular testing results from CLIA-certified laboratories (using tissue and/or blood) demonstrating hedgehog pathway relevant mutation (activating mutation of smoothened [SMO] or loss-of-function mutation of protein patched homolog-1 [PTCH-1])

    a) For participants screened using a blood assay: obtain tissue-based testing result confirming study eligibility (within first 4 weeks after enrollment)

  • All non-hematological adverse events related to any prior chemotherapy, surgery, or radiotherapy must have resolved to National Cancer Institute (NCI CTCAE) Grade less than or equal to (≤) 2 prior to starting therapy

Alectinib

  • Molecular testing results from CLIA-certified laboratories (using tissue and/or blood) demonstrating anaplastic lymphoma kinase (ALK) gene rearrangements, ALK mutations, ALK copy number gain or (for melanoma only) increased ALK expression or presence of ALK-alternative transcription initiation transcript (ALKATI) a) For participants screened using a blood assay: obtain tissue-based testing result confirming study eligibility (within first 4 weeks after enrollment)

Atezolizumab

  • Molecular testing results from CLIA-certified laboratories (using tissue) demonstrating elevated tissue tumor mutational burden (tTMB ≥10 mutations/ Megabase [Mb])
  • For patients where molecular testing was not performed using Foundation Medicine, submission of an archival or new pretreatment tissue sample is mandatory. For patients where molecular testing was performed using Foundation Medicine, submission of an archival or new pretreatment tissue sample is required, if available. The tissue sample must be submitted within 4 weeks after enrollment

General Exclusion Criteria:

  • Participants with hematologic malignancies
  • Concurrent administration of any other anti-cancer therapy (except male participants with prostate cancer receiving androgen blockade): Bisphosphonates and denosumab are allowed; Most recent anti-cancer therapy ≤28 days and have not recovered from the side effects, excluding alopecia; Radiation therapy within ≤14 days
  • Active or untreated
  • History of carcinomatous meningitis
  • Uncontrolled concurrent malignancy (early stage is allowed if not requiring active therapy or intervention)
  • Pregnant or breastfeeding women, or intending to become pregnant during the study
  • Any significant cardiovascular events within 6 months prior to study entry
  • Pulmonary embolism within 30 days prior to study entry
  • History or presence of ventricular or atrial dysrhythmia >Grade 2 per NCI CTCAE v4.0
  • Any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results
  • Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol

Study-Drug Specific Exclusion Criteria:

Trastuzumab plus Pertuzumab

  • Previous treatment with any HER2-targeted therapy

Erlotinib

  • Non-small cell lung cancer (NSCLC) or pancreatic cancer identified by exon 19 deletions or exon 21 L858R substitution mutations
  • EGFR amplifications in the absence of EGFR-activating mutations
  • Cancers with exon 20 mutations
  • Previous treatment with erlotinib or any other EGFR inhibitor
  • Inability to swallow pills
  • nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude absorption of erlotinib

Vemurafenib plus Cobimetinib

  • Malignant melanoma, papillary thyroid cancer, colorectal cancer, or hematologic malignancy including multiple myeloma
  • LVEF below institutional lower level of normal (LLN) or below 50%, whichever is lower
  • History of or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment, retinal vein occlusion (RVO), or neovascular macular degeneration
  • Presence of any of the following conditions, which are risk factors for RVO: Uncontrolled glaucoma with intraocular pressure >21 millimetres of mercury (mm Hg); Serum cholesterol ≥Grade 2; Hypertriglyceridemia ≥Grade 2; Hyperglycemia (fasting) ≥Grade 2; Grade ≥2 uncontrolled hypertension (participants with a history of hypertension controlled with anti-hypertensive medication to Grade \</=1 are eligible)
  • Prior or concurrent malignancy with known RAS mutation
  • Previous treatment with vemurafenib or any other BRAF inhibitor (prior sorafenib is allowed)
  • Previous treatment with cobimetinib or any other mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitor
  • Prior treatment with a RAF inhibitor
  • Inability to swallow pills
  • Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude absorption of vemurafenib
  • History of congenital long syndrome or mean (average of triplicate measurements) corrected QT (QTc) measured using Fridericia's method ≥450 millisecond (ms) at baseline or uncorrectable abnormalities in serum electrolytes (sodium, potassium, calcium, magnesium, phosphorus)

Vismodegib

  • Basal cell carcinoma of the skin, medulloblastoma, small-cell lung cancer, or hematologic malignancies
  • Previous treatment with vismodegib or any other hedgehog pathway inhibitor
  • Inability to swallow pills
  • Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude absorption of vismodegib

Alectinib

  • ALK-positive NSCLC, neuroblastoma, and childhood tumors
  • Previous treatment with alectinib or any other ALK inhibitor
  • Participants with symptomatic bradycardia
  • Administration of strong/potent cytochrome P3A4 () inhibitors or inducers within 14 days prior to the first dose of study treatment and while on treatment with alectinib
  • Inability to swallow pills
  • Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude absorption of alectinib

Atezolizumab

  • History of
  • Uncontrolled tumor pain
  • Asymptomatic metastatic lesions that would likely cause functional deficits or intractable pain with further growth (e.g., epidural metastasis that is not currently associated with spinal cord compression) should be considered for loco-regional therapy if appropriate prior to enrollment
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Patients with indwelling catheters are allowed
  • Uncontrolled or symptomatic hypercalcemia
  • Previous treatment with atezolizumab or another programmed death-1 ()/PD-L1 inhibitor
  • History of severe allergic, anaphylactic, or other reactions to chimeric or humanized antibodies or fusion proteins
  • Known hypersensitivity to biopharmaceutical agents produced in Chinese hamster ovary cells
  • Known allergy or hypersensitivity to any component of the atezolizumab formulation
  • Active or history of disease or immune deficiency
  • Prior allogeneic stem cell or solid organ transplantation
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • Positive (HIV) test, active virus (HBV) infection, active virus (HCV) infection or active tuberculosis
  • Severe infection within 4 weeks prior to initiation of study treatment
  • Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment
  • Significant cardiovascular disease, such as cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina
  • Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the course of the study
  • Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during the course of the study or within 5 months after the final dose of atezolizumab
  • History of other malignancy within 5 years prior to screening, with the exception of those with a negligible risk of metastasis or death, such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer
  • Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an drug, may affect the interpretation of the results, or may render the participant at high risk from treatment complications
  • Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies
  • Treatment with systemic immunostimulatory agents within 4 weeks or five half-lives of the drug (whichever is longer) prior to randomization
  • Treatment with systemic medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during the course of the study
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
673 participants (actual)

Study arms

  • Experimental
    Trastuzumab Plus Pertuzumab

    Participants will receive trastuzumab 8 milligrams per kilogram (mg/kg) intravenous (IV) infusion as loading dose, followed by 6 mg/kg IV infusion every 3 weeks; and pertuzumab 840 mg IV infusion as loading dose, followed by 420 mg IV infusion every 3 weeks.

    Drug: Trastuzumab · Drug: Pertuzumab

  • Experimental
    Atezolizumab

    Participants will receive atezolizumab 1200 mg IV infusion every 3 weeks.

    Drug: Atezolizumab

  • Experimental
    Vemurafenib

    Participants will receive vemurafenib 960 mg orally twice daily (BID) in each 28-day cycle.

    Drug: Vemurafenib

  • Experimental
    Vemurafenib Plus Cobimetinib

    Participants will receive vemurafenib 960 mg orally twice daily (BID) in each 28-day cycle; and cobimetinib 60 mg orally once daily for 21 days on and 7 days off in each 28-day cycle.

    Drug: Vemurafenib · Drug: Cobimetinib

  • Experimental
    Vismodegib

    Participants will receive vismodegib 150 mg orally once daily in each 28-day cycle.

    Drug: Vismodegib

  • Experimental
    Alectinib

    Participants will receive alectinib 600 mg orally BID in each 28-day cycle.

    Drug: Alectinib

  • Experimental
    Erlotinib

    Participants will receive erlotinib 150 mg orally once daily in each 28-day cycle.

    Drug: Erlotinib

Interventions

  • Trastuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

    Also known as: Herceptin

  • Pertuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

    Also known as: Perjeta

  • Erlotinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

    Also known as: Tarceva

  • Vemurafenib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

    Also known as: Zelboraf

  • Cobimetinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

    Also known as: Cotellic

  • Vismodegib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

    Also known as: Erivedge

  • Alectinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

    Also known as: Alecensa

  • Atezolizumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

    Also known as: Tecentriq

07

What researchers measure

Primary outcomes

  1. Percentage of Participants in All Tumor-Pathway Cohorts With Overall Response, as Assessed by the Investigator

    The Objective Response Rate (ORR) is defined as the percentage of patients whose best response on or before the first occurrence of disease progression is a complete response (CR) or partial response (PR). Tumor responses were assessed by investigators using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for all arms.

    Time frame: From the date of first study treatment until disease progression or death from any cause, whichever occurs first (72.1 months)

  2. Percentage of Atezolizumab-Treated Participants With Tissue Tumor Mutational Burden (tTMB) ≥16 Mutations/Mb With Overall Response, as Assessed by the Independent Review Committee (IRC)

    The Objective Response Rate (ORR) is defined as the proportion of patients whose best response on or before the first occurrence of disease progression is a complete response (CR) or partial response (PR). Tumor responses were assessed by Independent Review Committee (IRC) using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: From the date of first study treatment until disease progression or death from any cause, whichever occurs first (68.9 months)

Secondary outcomes

  1. Percentage of Participants With Disease Control

    Disease Control Rate (DCR) is defined as the proportion of patients whose best response is CR, PR or stable disease maintained more than 4 months (SD\>4 months). Tumor responses were assessed by investigators using RECIST version 1.1 for all arms.

    Time frame: From the date of first study treatment until disease progression or death from any cause, whichever occurs first (72.1 months)

  2. Progression-Free Survival (PFS)

    PFS is defined as the time from the start of study treatment to the first occurrence of disease progression, or death, whichever occurs first. Tumor responses were assessed by investigators using RECIST version 1.1 for all arms.

    Time frame: From the date of first study treatment until disease progression as assessed by the investigator, or death from any cause, whichever occurs first (72.1 months)

  3. Overall Survival (OS)

    Overall Survival (OS, months) is defined as the time from the date of the first study treatment (Day 1) to the date of death from any cause.

    Time frame: 87.5 months

  4. Duration of Response (DoR)

    Duration of Response (DoR) is defined as the time from the date of first documented response (CR or PR) to date of first occurrence of disease progression as determined by the investigator, or death from any cause, whichever occurs first.

    Time frame: From the date of first documented response (complete response [CR] or partial response [PR]) to the time of disease progression or death from any cause, whichever occurs first (70.8 months)

  5. Number of Participants With Adverse Events

    Incidence, nature, and severity of Adverse Events (AE), per the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 (NCI CTCAE v4.03) for participants enrolled prior to Version 6 of the protocol. The NCI CTCAE (v5.0) grading scale was used for assessing AE severity for participants enrolled under Version 6 of the protocol and subsequent versions.

    Time frame: From first study treatment administration to 30 days (45 days for vismodegib, 90 days for atezolizumab) after the last dose (up to approximately 6.3 years)

08

Results

Posted Jul 23, 2024

Participant flow

Participant flow — Overall Study
MilestoneTrastuzumab Plus PertuzumabAtezolizumabVemurafenibVemurafenib Plus CobimetinibVismodegibAlectinibErlotinib
Started3571755515372113
Completed282430300
Not completed3291515215342113
Withdrew: Death2801184613311612
Withdrew: Withdrawal by subject211332230
Withdrew: Lost to follow-up21510120
Withdrew: Reason not specified6520001
Withdrew: Study ended by sponsor1900000
Withdrew: Withdrew informed consent before receiving study drug0100000

Outcome measures

PrimaryPercentage of Participants in All Tumor-Pathway Cohorts With Overall Response, as Assessed by the Investigator

The Objective Response Rate (ORR) is defined as the percentage of patients whose best response on or before the first occurrence of disease progression is a complete response (CR) or partial response (PR). Tumor responses were assessed by investigators using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for all arms.

Time frame:
From the date of first study treatment until disease progression or death from any cause, whichever occurs first (72.1 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants in All Tumor-Pathway Cohorts With Overall Response, as Assessed by the Investigator
Percentage of ParticipantsTrastuzumab Plus PertuzumabAtezolizumabVemurafenibVemurafenib Plus CobimetinibVismodegibAlectinibErlotinib
Percentage of Participants in All Tumor-Pathway Cohorts With Overall Response, as Assessed by the Investigator21.0 (16.9 to 25.6)19.5 (13.9 to 26.2)25.5 (14.7 to 39.0)33.3 (11.8 to 61.6)10.8 (3.0 to 25.4)14.3 (3.0 to 36.3)7.7 (0.2 to 36.0)
PrimaryPercentage of Atezolizumab-Treated Participants With Tissue Tumor Mutational Burden (tTMB) ≥16 Mutations/Mb With Overall Response, as Assessed by the Independent Review Committee (IRC)

The Objective Response Rate (ORR) is defined as the proportion of patients whose best response on or before the first occurrence of disease progression is a complete response (CR) or partial response (PR). Tumor responses were assessed by Independent Review Committee (IRC) using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

Time frame:
From the date of first study treatment until disease progression or death from any cause, whichever occurs first (68.9 months)
Reported as:
Number · Percentage of Participants
Percentage of Atezolizumab-Treated Participants With Tissue Tumor Mutational Burden (tTMB) ≥16 Mutations/Mb With Overall Response, as Assessed by the Independent Review Committee (IRC)
Percentage of ParticipantsAtezolizumab
Percentage of Atezolizumab-Treated Participants With Tissue Tumor Mutational Burden (tTMB) ≥16 Mutations/Mb With Overall Response, as Assessed by the Independent Review Committee (IRC)29.5 (16.8 to 45.2)
SecondaryPercentage of Participants With Disease Control

Disease Control Rate (DCR) is defined as the proportion of patients whose best response is CR, PR or stable disease maintained more than 4 months (SD\>4 months). Tumor responses were assessed by investigators using RECIST version 1.1 for all arms.

Time frame:
From the date of first study treatment until disease progression or death from any cause, whichever occurs first (72.1 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Disease Control
Percentage of ParticipantsTrastuzumab Plus PertuzumabAtezolizumabVemurafenibVemurafenib Plus CobimetinibVismodegibAlectinibErlotinib
Percentage of Participants With Disease Control41.5 (36.3 to 46.8)39.1 (31.8 to 46.8)34.5 (22.2 to 48.6)66.7 (38.4 to 88.2)16.2 (6.2 to 32.0)42.9 (21.8 to 66.0)23.1 (5.0 to 53.8)
SecondaryProgression-Free Survival (PFS)

PFS is defined as the time from the start of study treatment to the first occurrence of disease progression, or death, whichever occurs first. Tumor responses were assessed by investigators using RECIST version 1.1 for all arms.

Time frame:
From the date of first study treatment until disease progression as assessed by the investigator, or death from any cause, whichever occurs first (72.1 months)
Reported as:
Median · Months
Progression-Free Survival (PFS)
MonthsTrastuzumab Plus PertuzumabAtezolizumabVemurafenibVemurafenib Plus CobimetinibVismodegibAlectinibErlotinib
Progression-Free Survival (PFS)2.8 (2.7 to 3.4)2.7 (1.6 to 3.0)3.1 (1.8 to 5.5)8.2 (3.9 to 19.5)1.8 (1.6 to 1.8)3.2 (1.7 to 6.6)1.8 (1.0 to 8.8)
SecondaryOverall Survival (OS)

Overall Survival (OS, months) is defined as the time from the date of the first study treatment (Day 1) to the date of death from any cause.

Time frame:
87.5 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsTrastuzumab Plus PertuzumabAtezolizumabVemurafenibVemurafenib Plus CobimetinibVismodegibAlectinibErlotinib
Overall Survival (OS)10.1 (8.7 to 11.7)13.5 (11.2 to 17.4)10.6 (5.2 to 13.5)15.6 (6.8 to 27.9)9.8 (4.0 to 13.4)14.1 (8.7 to 25.6)7.7 (2.2 to 15.0)
SecondaryDuration of Response (DoR)

Duration of Response (DoR) is defined as the time from the date of first documented response (CR or PR) to date of first occurrence of disease progression as determined by the investigator, or death from any cause, whichever occurs first.

Time frame:
From the date of first documented response (complete response [CR] or partial response [PR]) to the time of disease progression or death from any cause, whichever occurs first (70.8 months)
Reported as:
Median · Months
Duration of Response (DoR)
MonthsTrastuzumab Plus PertuzumabAtezolizumabVemurafenibVemurafenib Plus CobimetinibVismodegibAlectinibErlotinib
Duration of Response (DoR)7.3 (5.8 to 9.3)32.1 (6.9 to NA)6.0 (3.7 to 11.1)17.2 (7.4 to NA)14.1 (6.5 to NA)6.6 (6.0 to NA)8.3 (NA to NA)
SecondaryNumber of Participants With Adverse Events

Incidence, nature, and severity of Adverse Events (AE), per the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 (NCI CTCAE v4.03) for participants enrolled prior to Version 6 of the protocol. The NCI CTCAE (v5.0) grading scale was used for assessing AE severity for participants enrolled under Version 6 of the protocol and subsequent versions.

Time frame:
From first study treatment administration to 30 days (45 days for vismodegib, 90 days for atezolizumab) after the last dose (up to approximately 6.3 years)
Reported as:
Number · Participants
Number of Participants With Adverse Events
ParticipantsTrastuzumab Plus PertuzumabAtezolizumabVemurafenibVemurafenib Plus CobimetinibVismodegibAlectinibErlotinib
With at least one AE3341625415352112
With at least one SAE956221111373
With at least one Grade 3-5 AE14697371221114
With at least one Related AE261104491326199
With at least one Related SAE171465210
With at least one Grade 3-5 related AE4325256841
With at least one non-serious AESI5933000
With at least one AE leading to study drug withdrawn1715103101
With at least one AE leading to study drug interruption794527111164
With at least one AE leading to study drug reduction31283040
With at least one AE leading to death13522101

Adverse events

Collected over In the AE section, AE timeframe was from first study treatment administration to 30 days (45 days for vismodegib, 90 days for atezolizumab) after the last dose (up to approximately 6.3 years).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab Plus Pertuzumab285/357 (79.8%)95/357 (26.6%)313/357 (87.7%)
Atezolizumab118/174 (67.8%)62/174 (35.6%)147/174 (84.5%)
Vemurafenib46/55 (83.6%)21/55 (38.2%)50/55 (90.9%)
Vemurafenib Plus Cobimetinib13/15 (86.7%)11/15 (73.3%)12/15 (80%)
Vismodegib31/37 (83.8%)13/37 (35.1%)30/37 (81.1%)
Alectinib16/21 (76.2%)7/21 (33.3%)20/21 (95.2%)
Erlotinib12/13 (92.3%)3/13 (23.1%)11/13 (84.6%)
Most frequent serious events
Showing 10 of 155
Most frequent serious events
EventTrastuzumab Plus PertuzumabAtezolizumabVemurafenibVemurafenib Plus CobimetinibVismodegibAlectinibErlotinib
Small intestinal obstructionGastrointestinal disorders6/3573/1740/553/152/370/211/13
PyrexiaGeneral disorders1/3572/1741/552/150/370/210/13
SepsisInfections and infestations5/3574/1741/552/151/370/210/13
Ejection fraction decreasedInvestigations1/3570/1740/552/150/370/210/13
PneumoniaInfections and infestations4/3575/1742/550/152/370/211/13
FallInjury, poisoning and procedural complications2/3571/1740/550/150/370/211/13
Confusional statePsychiatric disorders1/3571/1740/550/150/370/211/13
Anaemia of malignant diseaseBlood and lymphatic system disorders0/3570/1740/551/150/370/210/13
Cardiac failureCardiac disorders1/3570/1740/551/150/370/210/13
Stress cardiomyopathyCardiac disorders0/3570/1740/551/150/370/210/13
Most frequent other events
Showing 10 of 37
Most frequent other events
EventTrastuzumab Plus PertuzumabAtezolizumabVemurafenibVemurafenib Plus CobimetinibVismodegibAlectinibErlotinib
NauseaGastrointestinal disorders80/35740/17421/558/158/376/214/13
FatigueGeneral disorders105/35746/17429/557/1514/377/215/13
DiarrhoeaGastrointestinal disorders129/35735/17413/557/159/373/216/13
Decreased appetiteMetabolism and nutrition disorders52/35722/17410/555/155/373/216/13
VomitingGastrointestinal disorders47/35726/17413/556/152/371/211/13
Oedema peripheralGeneral disorders26/35714/1745/556/156/377/210/13
Abdominal painGastrointestinal disorders43/35725/1746/555/151/374/211/13
ConstipationGastrointestinal disorders37/35723/1749/553/156/377/210/13
PyrexiaGeneral disorders36/35716/1744/555/152/371/214/13
ArthralgiaMusculoskeletal and connective tissue disorders44/35722/17418/554/152/372/210/13

Baseline characteristics

Baseline characteristics are provided for the safety population, which includes all participants who received at least one dose of study treatment. One participant who enrolled in the atezolizumab arm withdrew from the study before receiving any treatment and was therefore excluded.

Age, Categorical
Age, Categorical(Participants)Trastuzumab Plus PertuzumabAtezolizumabVemurafenibVemurafenib Plus CobimetinibVismodegibAlectinibErlotinibTotal
<=18 years00000000
Between 18 and 65 years2017732615116348
>=65 years1569723922107324
Age, Customized
Age, Customized(Years)Trastuzumab Plus PertuzumabAtezolizumabVemurafenibVemurafenib Plus CobimetinibVismodegibAlectinibErlotinibTotal
Mean61.0 ± 12.0665.1 ± 12.3361.3 ± 11.1563.2 ± 8.6963.5 ± 11.4163.5 ± 12.1764.5 ± 13.4162.4 ± 12.08
Sex: Female, Male
Sex: Female, Male(Participants)Trastuzumab Plus PertuzumabAtezolizumabVemurafenibVemurafenib Plus CobimetinibVismodegibAlectinibErlotinibTotal
Female1799829716125346
Male178762682198326
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Trastuzumab Plus PertuzumabAtezolizumabVemurafenibVemurafenib Plus CobimetinibVismodegibAlectinibErlotinibTotal
Hispanic or Latino19153110140
Not Hispanic or Latino3201524812362012600
Unknown or Not Reported1874201032
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Trastuzumab Plus PertuzumabAtezolizumabVemurafenibVemurafenib Plus CobimetinibVismodegibAlectinibErlotinibTotal
American Indian or Alaska Native33000017
Asian21111030137
Native Hawaiian or Other Pacific Islander01000001
Black or African American28207122060
White2881314613311810537
More than one race10000001
Unknown or Not Reported1681111129
09

Study locations

60 sites
  • Western Regional Medical Center at Cancer Treatment Centers of America
    Goodyear, Arizona 85338, United States
  • Mayo Clinic Arizona
    Phoenix, Arizona 85259, United States
  • Highlands Oncology Group
    Springdale, Arkansas 72762, United States
  • Science 37, Inc
    Culver City, California 90230, United States
  • City of Hope Comprehensive Cancer Center
    Duarte, California 91010, United States
  • Moores UCSD Cancer Center; Dept Clinical Trials Office
    La Jolla, California 92093-0698, United States
  • Eisenhower Medical Center
    Rancho Mirage, California 92270, United States
  • Stanford Comprehensive Cancer Center
    Stanford, California 94305, United States
  • Kaiser Permanente - Vallejo
    Vallejo, California 94589, United States
  • University of Colorado
    Aurora, Colorado 80045-2517, United States
  • SCRI Florida Cancer Specialists South
    Fort Myers, Florida 33916, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • Florida Hospital Cancer Inst; Memorial System Onc Clin Rsch
    Orlando, Florida 32804, United States
  • Florida Cancer Specialist, North Region
    Saint Petersburg, Florida 33705, United States
  • Florida Cancer Specialists, Research Department
    West Palm Beach, Florida 33401, United States
  • University Cancer & Blood Center, LLC; Research
    Athens, Georgia 30607, United States
  • Northeast Georgia Medical Center; Oncology Research Dept-5C
    Gainesville, Georgia 30501, United States
  • Southeastern Regional Medical Center, Inc.
    Newnan, Georgia 30265, United States
  • Northwestern University; Robert H. Lurie Comp Can Ctr; Northwestern Medicine Development Inst
    Chicago, Illinois 60611, United States
  • University Of Chicago Medical Center; Section Of Hematology/Oncology
    Chicago, Illinois 60637, United States
  • Midwestern Regional Med Center
    Zion, Illinois 60099, United States
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore, Maryland 21287, United States
  • Mayo Foundation
    Rochester, Minnesota 55905, United States
  • Research Medical Center - Antibiotic Research Associates, Inc.
    Kansas City, Missouri 64132, United States
  • Memorial Sloan Kettering - Monmouth
    Middletown, New Jersey 07748, United States
  • University of New Mexico Comprehensive Cancer Center
    Albuquerque, New Mexico 87102, United States
  • University of New Mexico Comprehensive Cancer Center - Albuquerque Cedar Street; Drug Shipment
    Albuquerque, New Mexico 87106, United States
  • University of New Mexico Comprehensive Cancer Center - Albuquerque Lang NE; Drug Shipment
    Albuquerque, New Mexico 87109, United States
  • University of New Mexico
    Albuquerque, New Mexico 87131, United States
  • San Juan Oncology Associates
    Farmington, New Mexico 87401, United States
  • Memorial Sloan Kettering Cancer Center at Westchester
    Harrison, New York 10604, United States
  • Weill Cornell Univ Medical Ctr; Breast Cancer Center
    New York, New York 10021, United States
  • Herbert Irving Comprehensive Cancer Center; Herbert Irving Pavillion
    New York, New York 10032, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Univ No Carolina School of Med; Physicians Office Bldg
    Chapel Hill, North Carolina 27599-7305v, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Wake Forest Univ Health Svcs; Internal Medicine
    Winston-Salem, North Carolina 27157, United States
  • Sanford Roger Maris Cancer Center
    Fargo, North Dakota 58102, United States
  • Oncology Hematology Care Inc
    Cincinnati, Ohio 45242, United States
  • Cleveland Clinic
    Cleveland, Ohio 44106, United States
  • University Hospitals of Cleveland
    Cleveland, Ohio 44106, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Providence Portland Medical Center
    Portland, Oregon 97213, United States
  • Abramson Cancer Center
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Eastern Regional Medical Ctr
    Philadelphia, Pennsylvania 19124, United States
  • UPMC - Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • Abington Mem Hosp-Abington; Rose. Can Ctr,Gyn Onc Ins
    Willow Grove, Pennsylvania 19090, United States
  • Sanford Cancer Cnt Onco Clinic
    Sioux Falls, South Dakota 57104, United States
  • Sarah Cannon Research Institute / Tennessee Oncology
    Chattanooga, Tennessee 37404, United States
  • West Clinic
    Germantown, Tennessee 38138, United States
  • Tennessee Cancer Specialists
    Knoxville, Tennessee 37920, United States
  • Tennessee Oncology - Nashville
    Nashville, Tennessee 37203, United States
  • Vanderbilt Ingram Cancer Clinic
    Nashville, Tennessee 37232, United States
  • The Center for Cancer and Blood Disorders - Fort Worth
    Fort Worth, Texas 76104, United States
  • MD Anderson
    Houston, Texas 77030, United States
  • Virginia Cancer Institute
    Richmond, Virginia 23229, United States
  • Northwest Medical Specialties
    Tacoma, Washington 98405, United States
  • University of Wisconsin
    Madison, Wisconsin 53705, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
10

References and documents

Publications

  • Narita Y, Yoshimoto T, Namai T, Asakawa T, Kawakami S, Gower-Page C, Reyes-Rivera I, Patel A, Nakamura Y. Pertuzumab Plus Trastuzumab for Treatment-Refractory HER2-Amplified Metastatic Colorectal Cancer: Comparison of the MyPathway Trial With a Real-World External Control Arm. JCO Clin Cancer Inform. 2022 May;6:e2200022. doi: 10.1200/CCI.22.00022. PubMed 35649212 ↗
  • Friedman CF, Hainsworth JD, Kurzrock R, Spigel DR, Burris HA, Sweeney CJ, Meric-Bernstam F, Wang Y, Levy J, Grindheim J, Shames DS, Schulze K, Patel A, Swanton C. Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. Cancer Discov. 2022 Mar 1;12(3):654-669. doi: 10.1158/2159-8290.CD-21-0450. PubMed 34876409 ↗
  • Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, Hainsworth J, Meric-Bernstam F, Swanton C, Sweeney CJ, Friedman CF, Bose R, Spigel DR, Wang Y, Levy J, Schulze K, Cuchelkar V, Patel A, Burris H. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021 Sep;22(9):1290-1300. doi: 10.1016/S1470-2045(21)00336-3. Epub 2021 Jul 30. PubMed 34339623 ↗
  • Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, Schulze K, Cuchelkar V, Hainsworth J. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019 Apr;20(4):518-530. doi: 10.1016/S1470-2045(18)30904-5. Epub 2019 Mar 8. PubMed 30857956 ↗
  • Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. J Clin Oncol. 2018 Feb 20;36(6):536-542. doi: 10.1200/JCO.2017.75.3780. Epub 2018 Jan 10. Erratum In: J Clin Oncol. 2019 Feb 1;37(4):360. doi: 10.1200/JCO.18.02263. PubMed 29320312 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient-level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/innovation/process/clinical-trials/data-sharing/).

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2014 to primary completion in May 2023, 109 months.

Results were first posted in Jul 2024, 1 year 1 month after primary completion.

Of 39 industry-sponsored phase 2 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 52. This study's 109 months is above that.

Counting every sponsor, half of 194 studies reached it within 52 months; a quarter within 36 and three quarters within 91.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2014
First posted
Mar 19, 2014
StartActual
Apr 14, 2014
Primary completionActual
May 24, 2023
CompletionActual
May 24, 2023
Results first posted
Jul 23, 2024
Last update
Jul 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02091141
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Mar 19, 2014
Start date
Apr 14, 2014
Primary completion
May 24, 2023
Completion
May 24, 2023
Results posted
Jul 23, 2024
Last update
Jul 23, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab · Pertuzumab · Erlotinib · Vemurafenib · Cobimetinib · HhAntag691 · Alectinib · Atezolizumab

Start the discussion